As the leading Duchenne muscular dystrophy charity in the UK, we want to find effective treatments for DMD and end its devastating impact. We connect the best researchers with industry, the NHS and families to advance and accelerate every stage of drug development.
We need to go further than anyone has before to find effective treatments. This means setting our ambitions high and overcoming every barrier in our way.
We’re going to do it faster, because this generation of people living with DMD can’t wait.
The only way we can achieve this is together. We create a network of mutual support for families. We collaborate with scientists and the pharmaceutical industry, bringing them together to share knowledge. And we work with health services so that patients get the care they need.
Join the fight to end Duchenne by cycling from London to Paris in 2022 for the 10th anniversary of our biggest fundraising event!
Find out more
Duchenne muscular dystrophy (DMD) is a life-limiting genetic disease which causes progressive muscle weakening.
About DMD
Join our fight to fund life-changing treatments for DMD by fundraising, donating, or joining an event.
Get involved
The DMD Hub is a network of trial sites carrying out clinical trials for Duchenne muscular dystrophy.
Visit the DMD Hub site
In a new transatlantic collaboration, Duchenne UK and the DMD Hub, PPMD and RTI International are conducting a study to explore attitudes towards gene therapy and gene editing from adults with Duchenne muscular dystrophy (DMD), parents and caregivers of children with DMD, and clinicians.
Read More
The JCVI has confirmed that people aged 5 and over with muscular dystrophy, or who receive high to moderate doses of corticosteroids, are eligible for vaccination against COVID. This includes children aged 5 and over whom they live with.
Read More
Last night we heard news from our friends at PPMD in the US that a young man has died while participating in Pfizer’s Phase 1B Open-Label study. Read Pfizer's statement to the community.
Read More
Biotech company MyoGene Bio have received a grant to study innovative gene-editing therapy, thanks to support from Duchenne UK and other charities.
Read More
Duchenne UK featured in The Times' Rare Disease report this week, with articles from CEO Emily Reuben and Project HERCULES' Fleur Chandler.
Read More
A MINI Electric wrapped in 2,000 smart Twinkly LED lights is starting a five-week tour to spread festive cheer and raise money for Duchenne UK alongside the MS Trust and Alzheimer’s Society.
Read More
In the last few months, the DMD Hub has recruited two new staff members to work with Emma Heslop, the DMD Hub Manager, and to look at new areas where the DMD Hub can develop support.
Read More
The European Medicines Agency (EMA) has approved the first measure collected using a digital wearable device for use in clinical trials for Duchenne muscular dystrophy.
Read More
Treat-NMD, the organisation that represents doctors and scientists working in neuromuscular disease, has released an important statement on stem cell tourism.
Read More
Sign up for the latest news on DMD research, upcoming events and ways to get involved.
